Abstract:e14039 Background: Astrocytoma and glioblastoma (GBM) are two main subtypes of glioma classified by WHO guide of center nervous system (CNS) tumors to different grades. GBM is the most malignant among all CNS tumors with a 5-year survival rate of less than 5%. Although the prognosis of patients with astrocytoma is better than that of GBM in general, astrocytoma patients with IDH wild-type have a similar prognosis as GBM. Exploring the molecular driving force behind the malignant phenotype of astrocytoma and GBM will help explain the diversity of glioma and discover new drug targets. Methods: We enrolled 12 patients with astrocytoma and 12 patients with GBM and performed whole-exome sequencing (WES) and RNA-seq analysis on tumor samples from the patients. Comparative analysis of somatic mutation, copy number variation, cytoband alteration and differently expressed genes were performed between astrocytoma and GBM. Immune cells infiltration was analyzed by CIBERSORT Algorithm with LM22 immune subsets. Results: This study includes 14 male patients and 10 female patients, and the median age was 45.5 (range, 18-68) years old. Seven patients had IDH1 mutation, including 6 patients with astrocytoma and 1 patient with GBM. Somatic mutation of KRT18, which is associated with cell apoptosis and adhesion by interacting with TRADD and Pinin , was significantly enriched in astrocytoma, but rare in GBM. Copy number loss of MTAP, which is a potential drug target and closely related to a poor prognosis of glioma, was found significantly enriched in GBM. Pathway enrichment analysis found that GBM was mainly enriched in tumor-related pathways, such as cell adhesion, cell division, and angiogenesis, but astrocytoma was mainly enriched in pathways with ion transport, cell-cell signaling and neurogenesis. Immune cells infiltration analysis showed that macrophages M0 was significantly enriched in GBM, and activated mast cells, monocytes and plasma cells were significantly enriched in astrocytoma. Conclusions: This study revealed the distinct characteristics of astrocytoma and GBM at the DNA and RNA levels. Somatic mutation of KRT18, which was first reported in glioma, may be closely related to the malignant phenotype of astrocytoma. Copy number loss of MTAP, which was associated with the susceptibility to purine starvation and specific chemotherapy, was a key genetic alterative gene in GBM and had the potential to become the therapeutic target of GBM.

Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model

Abstract C10: Neural Stem Cells and Lineage-Restricted Progenitors Can Initiate Malignant Astrocytoma Formation in Somatic Tumor Suppressor Mouse Models

Expression of Mutant p53 Proteins Implicates a Lineage Relationship between Neural Stem Cells and Malignant Astrocytic Glioma in a Murine Model

Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures

Haploinsufficiency of Adenomatous Polyposis Coli Coupled with Kirsten Rat Sarcoma Viral Oncogene Homologue Activation and P53 Loss Provokes High-Grade Glioblastoma Formation in Mice

TMOD-07. CELLULAR ORIGINS OF GLIOBLASTOMA: LESSONS FROM MOUSE MODELS

Loss of <i>p53</i> Concurrent with <i>RAS</i> and <i>TERT</i> Activation Induces Glioma Formation

Abstract LB-132: Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes

Abstract B035: A compendium of syngeneic, transplantable pediatric high-grade glioma models reveals subtype-specific therapeutic vulnerabilities

Loss of p53 Concurrent with RAS and TERT Activation Induces Glioma Formation

Gliomagenesis Arising From Pten- And Ink4a/Arf-Deficient Neural Progenitor Cells Is Mediated By The P53-Fbxw7/Cdc4 Pathway, Which Controls C-Myc

Tmod-35. Egfrviii Overexpression And Loss Of Mouse Specific Cdkn2A In Glial Cells Leads To Spontaneous Gliomagenesis In A Novel Mouse Model

Common Denominators of Self-renewal and Malignancy in Neural Stem Cells and Glioma

Murine Models of IDH-wild-type Glioblastoma Exhibit Spatial Segregation of Tumor Initiation and Manifestation During Evolution.

CB-04 * EPIGENETIC REGULATION OF GLIOBLASTOMA TUMORIGENICITY: A HYBRID MODEL

MODL-25. ANALYSIS OF TUMOR CELL HETEROGENEITY IN A HUMAN NEURAL PROGENITOR-BASED MODEL OF GLIOBLASTOMA REVEALS NEURODEVELOPMENTAL PROGRAMS AND CYTOSKELETAL DYNAMICS

Autochthonous mouse melanoma and mammary tumors do not express the pluripotency genes Oct4 and Nanog

Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells

The Mutational Landscape of MYCN, Lin28b and ALKF1174L Driven Murine Neuroblastoma Mimics Human Disease.

Integrated genomic and transcriptomic analysis identified KRT18 mutation and MTAP loss as key genetic alterations related to the prognosis of astrocytoma and glioblastoma.